ANG011

ANG011 is an orally delivered enzyme therapeutic being developed by Anagram Therapeutics for the treatment of congenital malabsorptive syndrome. The drug is engineered to break down specific carbohydrates in the gastrointestinal tract, addressing enzyme deficiencies that lead to malabsorption and its associated severe complications. As part of Anagram's pipeline of orally-delivered enzyme therapeutics, ANG011 functions through an enzyme replacement or supplementation approach, providing the necessary catalytic activity to metabolize nutrients that patients with congenital disorders cannot otherwise process. Currently in the preclinical development stage, ANG011 represents a novel approach to managing rare nutrient metabolism disorders through non-invasive, oral delivery.